Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.
| Cerebrolysin | TB-500 (Thymosin Beta-4) | |
|---|---|---|
| Category | Peptides | Peptides |
| Standard Dose | Research indicates 10-30 mL daily via intravenous infusion for neurological indications. 5-10 mL for cognitive optimization. | Research indicates 2-2.5 mg administered twice weekly via subcutaneous injection. |
| Timing | Morning administration preferred for cognitive effects. IV infusion over 15-20 minutes. | No strict timing requirements. Can be administered at any time of day. Systemic action means injection location is not critical. |
| Cycle Duration | 10-20 day intensive cycles repeated every 3-6 months. Some protocols use ongoing 3x weekly maintenance. | Loading phase: 4-6 weeks. Total cycle: 8-16 weeks. |
| Evidence Level | moderate_human | animal_plus_anecdotal |
Cerebrolysin is a porcine brain-derived peptide preparation containing a standardized mixture of low-molecular-weight neuropeptides (<10 kDa) and free amino acids obtained through enzymatic proteolysis. It exerts multimodal neurotrophic effects by simultaneously upregulating VEGF, BDNF, IGF-1, and NGF while downregulating TNF-alpha. Cerebrolysin increases furin protease concentration, which promotes pro-NGF to mature NGF conversion. It activates TrkB receptor signaling (BDNF/TrkB/CREB pathway), inhibits neuronal apoptosis, reduces microglial activation, and promotes neurogenesis.
Research indicates 10-30 mL daily via intravenous infusion for neurological indications. 5-10 mL for cognitive optimization.
Morning administration preferred for cognitive effects. IV infusion over 15-20 minutes.
10-20 day intensive cycles repeated every 3-6 months. Some protocols use ongoing 3x weekly maintenance.
TB-500 is a synthetic fragment of Thymosin Beta-4, a 43-amino acid protein that sequesters G-actin monomers, preventing premature polymerization and facilitating cellular migration and morphological changes essential for wound healing. It upregulates actin to promote cell migration, proliferation, and differentiation of stem/progenitor cells at injury sites. TB-500 also enhances angiogenesis, reduces inflammation, and promotes tissue remodeling through increased re-epithelialization and vascular density.
Research indicates 2-2.5 mg administered twice weekly via subcutaneous injection.
No strict timing requirements. Can be administered at any time of day. Systemic action means injection location is not critical.
Loading phase: 4-6 weeks. Total cycle: 8-16 weeks.
Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.
Get Your Free Protocol →or take the assessment →